Publications

The OBRI serves as a research platform that collects and analyzes data that is presented at scientific meetings in the form of publications and presentations.

Publications

• Movahedi M, Choquette D, Coupal L, Keystone E, Bombardier C, Bessette L. Impact of anti-rheumatic treatment on the individual components of the ACR composite score in patients with rheumatoid arthritis: real-world data. Clin Exp Rheumatol. 2024 Jun 6. doi: 10.55563/clinexprheumatol/6qobnr. Epub ahead of print. PMID: 38855967.
• Bhavsar SV, Movahedi M, Cesta A, Pope JE, Bombardier C. Retention of triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine compared to combination methotrexate and leflunomide in rheumatoid arthritis. Joint Bone Spine (2024), doi: https://doi.org/10.1016/j.jbspin.2024.105732
• Guo N, Li X, Movahedi M, Cesta A, Bombardier C. Biologics initiation in moderate versus severe rheumatoid arthritis: real-world experience from a Canadian registry. Clin Exp Rheumatol. 2024 May;42(5):1067-1074. doi: 10.55563/clinexprheumatol/mpevid. Epub 2024 Jan 31. PMID: 38372710.
• Samar Aboulenain, Xiuying Li, Mohammad Movahedi, Claire Bombardier, Bindee Kuriya.  Cardiovascular Risk Factors and the Risk of Discontinuation of Advanced Therapies Due to Treatment Failure in Rheumatoid Arthritis: Results From the Ontario Best Practices Research Initiative. ACR Open Rheumatology, 17 November 2023 https://doi.org/10.1002/acr2.11629
• Akhavan PS, Movahedi M, Cesta A, Bombardier C; and other OBRI investigators. Factors affecting the discrepancy between patient and physician global assessment in early rheumatoid arthritis: The Ontario Best Practices Research Initiative. Clin Exp Rheumatol. 2023 Jun 15. doi: 10.55563/clinexprheumatol/r7b8go. Epub ahead of print. PMID: 37382462
• Wong-Pack M, Hepworth E, Movahedi M, Kuriya B, Pope J, Keystone E, Thorne C, Ahluwalia V, Cesta A, Mously C, Bombardier C, Lau A, Aydin SZ. Impact of the COVID-19 pandemic on patients with rheumatoid arthritis: data from the Ontario Best Practices Research Initiative (OBRI). Rheumatol Adv Pract. 2023 Apr 26;7(2):rkad042. doi: 10.1093/rap/rkad042. PMID: 37179654; PMCID: PMC10172034
• Mohammad Movahedi, Denis Choquette, Louis Coupal, Angela Cesta, Xiuying Li, Edward C Keystone, Claire Bombardier, OBRI Investigators.  Discontinuation of tofacitinib and TNF inhibitors in patients with rheumatoid arthritis: analysis of pooled data from two registries in Canada. BMJ Open 2023;13:e063198. doi:10.1136/bmjopen-2022-063198.  Supplementary material.
• Li X, Cesta A, Movahedi M, Bombardier C. Late-onset rheumatoid arthritis has a similar time to remission as younger-onset rheumatoid arthritis: results from the Ontario Best Practices Research Initiative. Arthritis Res Ther. 2022 Nov 19;24(1):255. doi: 10.1186/s13075-022-02952-1. PMID: 36401335; PMCID: PMC9675233
• Mohammad Movahedi, Angela Cesta, Xiuying Li, Claire Bombardier, OBRI investigators. Disease activity trajectories for early and established rheumatoid arthritis: Real-world data from a rheumatoid arthritis cohort.  PLoS One. 2022 Sep 7;17(9):e0274264. doi: 10.1371/journal.pone.0274264. PMID: 36070307; PMCID: PMC9451079.
• Rampakakis E, Thorne C, Cesta A, Movahedi M, Li X, Mously C, Ahluwalia V, Brophy J, Ciaschini P, Keystone E, Lau A, Major G, Pavlova V, Pope JE, Bombardier C. Medical cannabis use by rheumatology patients in routine clinical care: results from The Ontario Best Practices Research Initiative. Clin Exp Rheumatol. 2022 May 23. doi: 10.55563/clinexprheumatol/b85xu5. Epub ahead of print. PMID: 35616591.
• Keystone E, Movahedi M, Cesta A, Bombardier C, Sampalis JS, Rampakakis E. Differential influence of Clinical Disease Activity Index components based on disease state in rheumatoid arthritis patients: real-world results from the Ontario Best Practices Research Initiative. Clin Exp Rheumatol. 2022 Mar 30. doi: 10.55563/clinexprheumatol/86frzq. Epub ahead of print. PMID: 35383561.
• Movahedi M, Cesta A, Li X, Keystone EC, Bombardier C; OBRI Investigators. Physician- and Patient-reported Effectiveness Are Similar for Tofacitinib and TNFi in Rheumatoid Arthritis: Data From a Rheumatoid Arthritis Registry. J Rheumatol. 2022 May;49(5):447-453. doi: 10.3899/jrheum.211066. Epub 2022 Feb 15. PMID: 35169051.  Supplementary tables available here.
• Hazlewood GS, Bombardier C, Li X, Movahedi M, Choquette D, Coupal L, Bykerk VP, Schieir O, Mosher D, Marshall DA, Bernatsky S, Spencer N, Richards DP, Proulx L, Barber CEH; OBRI, RHUMADATA, CATCH Investigators, and the Rheum4U Team. Heterogeneity in Patient Characteristics and Differences in Treatment Across 4 Canadian Rheumatoid Arthritis Cohorts. J Rheumatol. 2022 Jan;49(1):16-25. doi: 10.3899/jrheum.201688. Epub 2021 Aug 1. PMID: 34334357.
• Cui K, Movahedi M, Bombardier C, Kuriya B. Cardiovascular risk factors are negatively associated with rheumatoid arthritis disease outcomes. Ther Adv Musculoskelet Dis. 2021 Feb 15;13:1759720X20981217. doi: 10.1177/1759720X20981217. PMID: 33643444; PMCID: PMC7890714.
• Hepworth E, Movahedi M, Rampakakis E, Mirza R, Lau A, Cesta A, Pope J, Sampalis JS, Bombardier C, OBRI Investigators. Changes in Market Share of Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for Treatment of Rheumatoid Arthritis: Results from the Ontario Best-Practice Research Initiative Database.  Current Rheumatology Reviews. 2021, Vol 17;3. doi: 10.2174/1573397116666201211130337
• Pope, J.,  Rampakakis, E., Movahedi, M., Cesta, A., Sampalis, J.S., Bombardier, C. for OBRI investigators. Time to remission in swollen joints is far faster than patient reported outcomes in rheumatoid arthritis: results from the Ontario Best Practices Research Initiative (OBRI). Rheumatology, 2020August13. keaa343, https://doi.org/10.1093/rheumatology/keaa343
• Movahedi, M., Hepworth, E., Mirza, R., Cesta, A., Larche, M. and Bombardier, C. Discontinuation of Biologic Therapy due to Lack/loss of Response and Adverse Events is Similar Between TNFi and non-TNFi Class: Results from a Real World Rheumatoid Arthritis Cohort. https://doi.org/10.1016/j.semarthrit.2020.06.020
• Fullerton L, Brooks S, Sweezie R, Ahluwalia Bombardier C and Gigliardi A. Patient, Rheumatologist, and Therapist perspectives on the Implementation of an Allied Health Rheumatology Triage (AHRT) Initiative in Ontario Rheumatology Clinics.  Pragmat Obs Res. 2020 Jan 28;11:1-12. doi: 10.2147/POR.S213966. eCollection 2020
• Keystone E, Rampakakis E, Movahedi M, Cesta A, Stutz M1, Sampalis JS, Nantel F, Maslova K, Bombardier C. Towards Defining Primary and Secondary Non-Response in Rheumatoid Arthritis Patients Treated with Anti-TNFs: Results from the BioTRAC and OBRI Registries. Journal of Rheumatology, 2020 Apr;47(4):510-517.  doi: 10.3899/jrheum.190102. Epub 2019 Jul 1.
• Movahedi M, Cesta A, Li X, Bombardier C. Collection of Anti-Rheumatic Medication Data from Both Patients and Rheumatologists Shows Strong Agreement in a Real World Clinical Cohort: Results from The Ontario Best Practices Research Initiative (OBRI) a Rheumatoid Arthritis Cohort. Journal of Clinical Epidemiology, 2019 Oct;114:95-103. doi: 10.1016/j.jclinepi.2019.06.012. Epub 2019 Jun
• Li G, Chen M, Li X, Cesta A, Lau A, Thabane L, Adachi JD, Tian J, Bombardier C.  Frailty and risk of osteoporotic fractures in patients with rheumatoid arthritis: Data from the Ontario Biologics Research Initiative.  Bone. 2019 Oct;127:129-134. doi: 10.1016/j.bone.2019.06.006. Epub 2019 Jun 8
• Lau A, Thorne C, Movahedi M, Rampakakis E, Cesta A, Li X, Couto S, Sampalis JS, Bombardier C. Effect of Concomitant Disease-modifying Antirheumatic Drugs and Methotrexate Administration Route on Biologic Treatment Durability in Rheumatoid Arthritis: OBRI Cohort . Journal of Rheumatology. 2019 Aug;46(8):874-886. doi: 10.3899/jrheum.180486. Epub 2019 Apr 15.  PMID: 30988121
• Janet Pope, Mohammad Movahedi, Emmanouil Rampakakis, Angela Cesta, John S. Sampalis, Claire Bombardier and OBRI investigators. ACPA and RF as Predictors of Sustained Clinical Remission in Rheumatoid Arthritis Patients: Results from the Ontario Best Practices Research Initiative (OBRI). RMD Open 2018;4:e000738. doi: 10.1136/rmdopen-2018-000738
• Mohammad Movahedi, Raman Joshi, Emmanouil Rampakakis, Carter Thorne, Angela Cesta, John S. Sampalis, Claire Bombardier, on behalf of Other OBRI Investigators.  Impact of residential area on the management of rheumatoid arthritis patients initiating their first biologic DMARD; Results from the Ontario Best Practices Research Initiative (OBRI). Medicine (Baltimore). 2019 May;98(20):e15517. doi: 10.1097/MD.0000000000015517.
• Kuriya B, Joshi R, Movahedi M, Rampakakis E, Sampalis JS, Bombardier C. High Disease Activity is Associated with Symptomatic Depression and Predicts Persistent Symptomatic Depression in Early Rheumatoid Arthritis: Results from The Ontario Best Practices Research Initiative (OBRI). Journal of Rheumatology, May 2018, jrheum.171195; DOI://doi.org/10.3899/jrheum.171195.
• Pope JE, Rampakakis E, Movahedi M, Cesta A, Li X, Couto S, Sampalis JS, Bombardier C and the Ontario Best Practices Research Initiative Investigators. Treatment patterns in rheumatoid arthritis after discontinuation of methotrexate: data from the Ontario Best Practices Research Initiative (OBRI). Clinical and Experimental Rheumatology, 2017 Oct 23.  [Epub ahead of print]
• Ahluwalia V, Rampakakis E, Movahedi M, Cesta A, Li X, Sampalis JS, Bombardier C and the Ontario Best Practices Research Initiative Investigators.  Predictors of patient decision to discontinue anti-rheumatic medication in patients with rheumatoid arthritis: results from the Ontario Best Practices Research Initiative. Clinical Rheumatology 2017 Nov:36(11):2421-2460.
• Ruban TN, Jacob B, Pope JE, Keystone EC, Bombardier C, Kuriya B. The influence of age at disease onset on disease activity and disability: results from the Ontario Best Practices Research Initiative. Clinical Rheumatology. Aug 2015.
• Widdifield, J. Bernatsky, S. Paterson, MJ, Tomlinson G, Tu K, Kuriya B, Thorne CJ, Pope JE, Hollands S, Bombardier C.  Trends in excess mortality among patients with rheumatoid arthritis in Ontario, Canada. Arthritis Care and Research. Jan 2015.
• Widdifield J, Bombardier C, Bernatsky S, Paterson JM, Green D, Young J, Ivers N, Butt DA, Jaakkimainen L, Thorne C, Tu K. An administrative data validation study of the accuracy of algorithms for identifying rheumatoid arthritis: The influence of the reference standard on algorithm performance. BMC Musculoskeletal Disorders. 2014;15(1):216.
• Widdifield J, Paterson JM, Bernatsky S, Tu K, Tomlinson G, Kuriya B, Thorne C, Bombardier C. The epidemiology of rheumatoid arthritis in Ontario, Canada. Arthritis & Rheumatology. 2014;66(4):786-93.
• Harold A, Leslie J, Wilkins A, Collins S, Begley H, Heslegrave R, Bombardier C. Research practice in the digital age: A new model for consent and governance in longitudinal cohort and population-based observational studies. Technical Report. Ontario Best Practices Research Initiative (OBRI). 2014.
• Harold A, Leslie J, Wilkins A, Cesta A, Collins S, Begley H, Heslegrave R, Bombardier C. Theoretical framework for e-consent governance and the design and evaluation of research study protocols. Technical Report. Ontario Best Practices Research Initiative (OBRI). 2014.
• Harold A, Leslie J, Wilkins A, Cesta A, Collins S, Heslegrave R, Bombardier C. Impact of Information Technology on research practice: The future of electronic data capture of participant reported outcomes. Technical Report. Ontario Best Practices Research Initiative (OBRI). 2014
• Widdifield J, Paterson JM, Bernatsky S, Tu K, Thorne JC, Ivers N, Butt D, Jaakkimainen L, Gunraj N, Ahluwalia V, Bombardier C. Access to rheumatologists among patients with newly diagnosed rheumatoid arthritis in a Canadian universal public healthcare system. BMJ Open. 2014 Jan;4:1-8.
• Widdifield J, Paterson JM, Bernatsky S, Tu K, Thorne JC, Ahluwalia V, Ivers N, Butt D, Jaakkimainen L, Tomlinson G, Bombardier C. The rising burden of rheumatoid arthritis surpasses rheumatology supply in Ontario. Canadian Journal of Public Health. 2013 Nov-Dec;104(7):e450-5.
• Widdifield J, Bernatsky S, Paterson JM, Gunraj N, Thorne JC, Pope JE, Cividino A, Bombardier C. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res. 2013;65(3):353-361.
• Widdifield J, Bernatsky S, Paterson JM, Tu K, Ng R, Thorne JC, Pope J, Bombardier C. Accuracy of Canadian health administrative databases in identifying patients with Rheumatoid Arthritis: A validation study using the medical records of rheumatologists. Arthritis Care & Research. 2013;65(10):1582–91.
• Widdifield J, Labrecque J, Lix L, Paterson JM, Bernatsky S, Tu K, Ivers N, Bombardier C. A systematic review and critical appraisal of validation studies to identify rheumatic diseases in health administrative databases. Arthritis Care Res. 2013;65(9):1490-503.
• Bombardier C, Mian, S. Quality Indicators in rheumatoid arthritis: Using measurement to promote quality improvement. Ann Rheum Dis. 2012;72(Suppl):ii128–ii31.
• Widdifield J, Bernatsky S, Paterson JM, Thorne JC, Cividino A, Pope J, Gunraj N, Bombardier C. Quality care in seniors with new-onset rheumatoid arthritis: A Canadian perspective. Arthritis Care Res (Hoboken). 2011;63(1):53-57.
• Pease C, Pope, JE, Thorne C, Haraoui BP, Truong D, Bombardier C, Widdifield J, Psaradellis E, Sampalis JS, Bonner A. Canadian variation by province in rheumatoid arthritis initiating anti−tumor necrosis factor therapy: Results from the optimization of adalimumab trial. J Rheumatol. 2010;37(12):2469-74.
• Pease C, Pope JE, Truong C, Bombardier C, Widdifield J, Thorne JC, Haraoui BP, Psaradellis E, Sampalis JS, Bonner A. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy. Semin Arthritis Rheum. 2011;41(1):81-9.
• Van der Velde G, Pham B, Machado M, Ieraci L, Witteman W, Bombardier C, Krahn M. Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: A systematic review. Arthritis Care Res (Hoboken). 2011;63(1):65-78.
• Bernatsky S, Paterson M, Thorne C, Cividino A, Pope J, Hux J, Bombardier C. Potential effects of a national consensus statement on optimal treatment of early rheumatoid arthritis in Ontario. Scand J Rheumatol. 2009;38(5):390-1.